UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 13F
Form 13F COVER PAGE
Report for the Calendar Year or Quarter Ended: 6/30/02
-----------------------
Check Here if Amendment / /; Amendment Number:
---------
This Amendment (Check only one.): / / is a restatement.
/ / adds new holdings entries.
Institutional Investment Manager Filing this Report:
Name: Hambrecht & Quist Capital Management Inc.
-----------------------------------------
Address: 30 Rowes Wharf
-----------------------------------------
Boston, MA 02110
-----------------------------------------
-----------------------------------------
Form 13F File Number: 28-04219
---------------------
The institutional investment manager filing this report and the person by
whom it is signed hereby represent that the person signing the report is
authorized to submit it, that all information contained herein is true,
correct and complete, and that it is understood that all required items,
statements, schedules, lists, and tables, are considered integral parts of
this form.
Person Signing this Report on Behalf of Reporting Manager:
Name: Kim Carroll
-------------------------------
Title: Treasurer
-------------------------------
Phone: 617-310-0537
-------------------------------
Signature, Place, and Date of Signing:
Kim Carroll Boston, MA 7/30/02
------------------------------- ----------------- -------------
[Signature] [City, State] [Date]
Report Type (Check only one.):
/X/ 13F HOLDINGS REPORT. (Check here if all holdings of this reporting
manager are reported in this report.)
/ / 13F NOTICE. (Check here if no holdings reported are in this report,
and all holdings are reported by other reporting manager(s).)
/ / 13F COMBINATION REPORT. (Check here if a portion of the holdings for
this reporting manager are reported in this report and a portion are
reported by other reporting manager(s).)
FORM 13F INFORMATION TABLE
NAME OF REPORTING MANAGER: HAMBRECHT & QUIST CAPITAL MANAGEMENT
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
---------------------------- -------------- --------- ------------ ------------------ -------- -------- ----------------------
VALUE SHARES OR SH/ PUT/ INVSTMNT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DSCRETN MANAGERS SOLE SHARED NONE
---------------------------- -------------- --------- ----------- --------- --- ---- -------- -------- ------ -------- ------
Abgenix Common 00039B107 $4,851,000 495,000 SOLE NA X
Adolor Common 00724X102 $4,372,258 388,300 SOLE NA X
Aradigm Common 038505103 1,527,050 350,000 SOLE NA X
ATS Medical Common 002083103 350,000 636,364 SOLE NA X
Biofield Common 090591207 439,434 878,866 SOLE NA X
Biofield (Restricted) Common 090591207 400,000 1,000,000 SOLE NA X
Bioject Medical Technologies Common 09059T206 868,700 238,000 SOLE NA X
Biopure Common 09065H915 1,298,557 169,746 SOLE NA X
BioTransplant Common 09066Y107 1,795,545 712,518 SOLE NA X
Catalytica Energy Systems Common 148884109 406,107 128,515 SOLE NA X
Celgene Common 151020104 10,557,000 90,000 SOLE NA X
Cephalon Common 156708109 4,068,000 90,000 SOLE NA X
Corixa Common 21887F100 2,681,501 391,460 SOLE NA X
Cubist Pharmaceuticals Common 229990981 9,014,827 958,005 SOLE NA X
Curis Common 231269101 184,830 151,500 SOLE NA X
CV Therapeutics Common 126667104 10,172,236 546,307 SOLE NA X
Cytyc Common 232946103 3,309,260 434,286 SOLE NA X
deCODE Genetics Common 24386104 3,486,600 745,000 SOLE NA X
Digene Common 253752109 323,449 27,500 SOLE NA X
Dyax Common 26746E103 2,707,634 694,265 SOLE NA X
Endocardial Solutions Common 292962107 12,649,995 1,666,666 SOLE NA X
Endologix Common 292665106 310,200 330,000 SOLE NA X
Envirogen Common 294040100 20,521 20,833 SOLE NA X
EP MedSystems Common 26881P103 2,418,750 1,075,000 SOLE NA X
Exelixis Common 30161Q104 5,862,105 778,500 SOLE NA X
Genzyme Common 372917104 5,175,560 269,000 SOLE NA X
Gilead Sciences Common 37555B103 23,891,792 726,636 SOLE NA X
IDEXX Laboratories Common 45168D104 6,447,500 250,000 SOLE NA X
IVAX Common 465823102 2,786,400 258,000 SOLE NA X
Lexicon Genetics Common 5288872104 638,015 130,500 SOLE NA X
Lynx Therapeutics Common 551812308 2,560,650 1,985,000 SOLE NA X
Martek Biosciences Common 572901106 16,322,286 780,224 SOLE NA X
MedImmune Common 584699102 8,712,000 330,000 SOLE NA X
Molecular Devices Common 60851C107 5,175,671 290,768 SOLE NA X
Orthovita Common 68750U102 2,907,000 1,700,000 SOLE NA X
Quintiles Transnational Common 748767100 1,909,721 152,900 SOLE NA X
Rigel Pharmaceuticals Common 766559108 3,750,375 1,027,500 SOLE NA X
Telik Common 87959M109 8,333,313 666,665 SOLE NA X
Teva Pharmaceutical Industries Common 881624209 6,678,000 100,000 SOLE NA X
Transkaryotic Therapies Common 893735100 13,790,928 382,550 SOLE NA X
FORM 13F INFORMATION TABLE
NAME OF REPORTING MANAGER: HAMBRECHT & QUIST CAPITAL MANAGEMENT
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
----------------------- -------------- --------- ------------ ------------------ -------- -------- -----------------------
VALUE SHARES OR SH/ PUT/ INVSTMNT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DSCRETN MANAGERS SOLE SHARED NONE
----------------------- -------------- --------- ------------ --------- --- ---- -------- -------- ------ -------- ------
Tularik Common 899165104 3,717,564 405,405 SOLE NA X
Verdant Brands Common 923366108 228 38,000 SOLE NA X
Versicor Common 925314106 9,373,856 696,941 SOLE NA X
Vertex Pharmaceuticals Common 92532F100 3,088,316 189,700 SOLE NA X
WebMD Common 94769M105 3,786,175 672,500 SOLE NA X
COLUMN TOTALS $213,120,909
Form 13F SUMMARY PAGE
Report Summary:
Number of Other Included Managers: 0
--------------------
Form 13F Information Table Entry Total: 45
--------------------
Form 13F Information Table Value Total: $ 213,120,909
--------------------
(thousands)
List of Other Included Managers:
Provide a numbered list of the name(s) and Form 13F file number(s) of all
institutional investment managers with respect to which this report is filed,
other than the manager filing this report.